Chaudhary Preety, Kumari Sweta, Dewan Pooja, Gomber Sunil, Ahmed Rafat S, Kotru Mrinalini
Pediatrics and Child Health, University College of Medical Sciences, Delhi, IND.
Pediatrics, University College of Medical Sciences, Delhi, IND.
Cureus. 2023 Mar 10;15(3):e35968. doi: 10.7759/cureus.35968. eCollection 2023 Mar.
Introduction Plasma antioxidant capacity in children receiving chemotherapy decreases due to the effect of the disease and chemotherapy. Increased oxidative stress (OS) predisposes to an increased risk for chemotherapy-related toxicity and febrile neutropenic episodes. Materials and methods We conducted this case-control study in the hematology-oncology unit of the department of pediatrics of a tertiary hospital in Delhi, India, from November 2017 to March 2019 to compare OS between children with acute lymphoblastic leukemia (ALL) and healthy controls. We estimated the trends in OS as measured by the plasma total antioxidant capacity (TAC) and thiobarbituric acid reactive substance (TBARS) levels at baseline and at the completion of induction I (four weeks), induction II (eight weeks), and induction IIA-consolidation (16 weeks) phases of chemotherapy in children with ALL. We also assessed the change in OS during different phases of initial treatment and studied the association between OS and the hematological toxicity of chemotherapy (determined by the need for blood component therapy and the number of febrile neutropenic episodes) and serum cobalamin and folate levels. Results OS was significantly higher in children with ALL at diagnosis (n=23) compared to controls (n=19). The median (interquartile range (IQR)) TAC levels (mM) were significantly lower (1.21 (1.05-1.26) versus 1.28 (1.26-1.32), P=0.006), and TBARS levels (nmol/mL) were significantly higher (312.0 (216.6-398.0) versus 58.5 (46.2-67.2), P<0.001) in children with ALL at diagnosis compared to controls. OS was highest at the end of the induction I phase (four weeks) despite the patients being in clinical and hematological remission. OS at the completion of intensive chemotherapy (16 weeks) was higher than at diagnosis. A significant correlation was found between serum folate levels and TAC levels at baseline (P=0.03). Serum cobalamin levels, the need for blood component therapy, and the number of febrile neutropenic episodes did not have any association with OS. Conclusion Children with ALL had significantly higher OS compared to controls, indicating that underlying disease affects the oxidative balance unfavorably. Chemotherapy itself increases oxidative stress.
接受化疗的儿童血浆抗氧化能力会因疾病和化疗的影响而降低。氧化应激(OS)增加会使化疗相关毒性和发热性中性粒细胞减少发作的风险升高。
我们于2017年11月至2019年3月在印度德里一家三级医院儿科的血液肿瘤病房开展了这项病例对照研究,以比较急性淋巴细胞白血病(ALL)患儿与健康对照者之间的氧化应激情况。我们估计了ALL患儿在化疗诱导I期(四周)、诱导II期(八周)和诱导IIA巩固期(16周)开始时及结束时,通过血浆总抗氧化能力(TAC)和硫代巴比妥酸反应性物质(TBARS)水平所测得的氧化应激趋势。我们还评估了初始治疗不同阶段氧化应激的变化,并研究了氧化应激与化疗血液学毒性(由血液成分治疗需求和发热性中性粒细胞减少发作次数确定)以及血清钴胺素和叶酸水平之间的关联。
与对照组(n = 19)相比,ALL患儿在诊断时(n = 23)的氧化应激显著更高。ALL患儿诊断时的TAC水平中位数(四分位间距(IQR))(mM)显著更低(1.21(1.05 - 1.26)对1.28(1.26 - 1.32),P = 0.006),TBARS水平(nmol/mL)显著更高(312.0(216.6 - 398.0)对58.5(46.2 - 67.2),P < 0.001)。尽管患者处于临床和血液学缓解状态,但诱导I期(四周)结束时氧化应激最高。强化化疗结束时(16周)的氧化应激高于诊断时。发现基线时血清叶酸水平与TAC水平之间存在显著相关性(P = 0.03)。血清钴胺素水平、血液成分治疗需求和发热性中性粒细胞减少发作次数与氧化应激均无关联。
与对照组相比,ALL患儿的氧化应激显著更高,表明潜在疾病对氧化平衡产生不利影响。化疗本身会增加氧化应激。